Hormone replacement therapy and diabetes can coexist — diabetes is not a contraindication to HRT, and many women with type 1 or type 2 diabetes benefit from symptom relief and a modest improvement in glycemic control. Transdermal estrogen (patch, gel, spray) is generally preferred over oral in women with diabetes because it bypasses hepatic first-pass metabolism and has a lower clotting risk. The timing hypothesis supports starting HRT within 10 years of menopause or before age 60 for the most favorable risk-benefit profile. Compounded “bioidentical” preparations are not FDA-approved; FDA-approved estradiol and progesterone are also bioidentical and have predictable dosing.
What HRT Is
Hormone replacement therapy — increasingly called menopausal hormone therapy (MHT) — replaces the estrogen (and often progestogen) that declines at menopause. It is the most effective treatment for vasomotor symptoms (hot flashes, night sweats) and the genitourinary syndrome of menopause (vaginal dryness, painful intercourse, urinary symptoms).
| Regimen Type | Who It’s For |
|---|---|
| Estrogen-only | Women without a uterus (after hysterectomy) |
| Estrogen + progestogen | Women with an intact uterus (progestogen protects the endometrium) |
| Vaginal estrogen alone | Local symptoms only — vaginal dryness, painful sex, urinary symptoms |
| Combined oral contraceptives (low dose) | Perimenopausal women still needing contraception |
| Tibolone (not US) | Synthetic steroid with estrogenic, progestogenic, and androgenic effects |
| Bazedoxifene/conjugated estrogens (Duavee) | Alternative to estrogen plus progestogen |
Routes of Administration
- Oral estrogen (estradiol, conjugated estrogens): Daily pill, undergoes hepatic first-pass — affects triglycerides, clotting factors, SHBG
- Transdermal patch (Climara, Vivelle-Dot, Minivelle): Applied 1 to 2 times weekly, steady delivery, no first-pass
- Transdermal gel (Estrogel, Divigel, Elestrin): Daily application, dose-flexible
- Transdermal spray (Evamist): Daily, applied to forearm
- Vaginal ring (Femring — systemic dose, Estring — local dose): Inserted every 3 months
- Vaginal cream, tablet, insert (Estrace, Vagifem, Imvexxy): Local effect only, very low systemic absorption
- Progestogens: Oral micronized progesterone (Prometrium), levonorgestrel IUD (Mirena — endometrial protection), oral medroxyprogesterone
Why Transdermal Is Preferred in Diabetes
The major reason: hepatic first-pass effects. Oral estrogen, after absorption from the gut, passes through the liver before reaching general circulation. This produces effects that matter especially for women with diabetes:
- Increased triglycerides — already often elevated in T2D
- Increased clotting factor production — small absolute increase in venous thromboembolism risk
- Increased SHBG (sex hormone binding globulin) — can lower free testosterone
- Effects on inflammatory markers (CRP)
- Effects on gallbladder — increased risk of gallstones
Transdermal estrogen bypasses this first-pass and largely avoids these effects, with comparable symptom relief.
HRT Effects on Glucose and Insulin Sensitivity
- Most studies show modest improvement in insulin sensitivity — typically 5 to 15 percent
- A1C often drops by 0.2 to 0.5 percentage points
- Fasting glucose tends to decrease modestly
- Estrogen-only HRT has a more favorable metabolic profile than combined HRT in most studies
- The progestogen choice matters — micronized progesterone is metabolically neutral; some synthetic progestins are less favorable
- Insulin doses may need slight reduction after starting HRT and slight increase after stopping
Understanding the Women’s Health Initiative
The WHI, published in 2002, was the largest randomized trial of HRT and changed practice dramatically — sometimes in oversimplified ways. Key findings:
- Combined estrogen + medroxyprogesterone in women average age 63 showed small increases in breast cancer, stroke, clots, and heart events
- Estrogen-only in women without a uterus showed a different pattern — no increase in breast cancer, possible cardiovascular benefit in younger participants
- Subsequent reanalyses by age and time since menopause supported the timing hypothesis
- For women under 60 or within 10 years of menopause, the risk-benefit balance is much more favorable
- For women over 60 starting HRT for the first time, risks generally outweigh benefits
The current NAMS position statement integrates these findings — HRT is appropriate for symptomatic women in the early window, with route, dose, and duration individualized.
The Timing Hypothesis
| Timing | Risk-Benefit Profile |
|---|---|
| Within 10 years of menopause, age <60 | Most favorable; modest cardiovascular benefit possible; bone benefit; symptom relief |
| 10–20 years after menopause | Less favorable; case-by-case |
| >20 years after menopause or age >70 | Risks generally exceed benefits; not recommended to initiate |
Contraindications to HRT
- Known or suspected breast cancer
- Known or suspected estrogen-sensitive cancer
- Active or recent (past year) venous thromboembolism
- Active or recent stroke or heart attack
- Active liver disease
- Unexplained vaginal bleeding
- Pregnancy
- Known hypersensitivity to components
- Untreated severe hypertension
Considerations Specific to Diabetes
- Cardiovascular risk assessment before starting — many women with diabetes have additional risk factors
- Transdermal preferred unless specific reason for oral
- Micronized progesterone often preferred over synthetic progestins for endometrial protection
- Monitor A1C, weight, blood pressure after starting
- Insulin or oral medication doses may need adjustment
- Check lipid panel before and after
- Discuss with endocrinologist before adding HRT, especially if cardiovascular disease is established
- Review all complications and related conditions as part of the assessment
Bioidentical and Compounded Hormones
“Bioidentical” is a marketing term, not a regulatory category. FDA-approved estradiol (the predominant human estrogen) and FDA-approved micronized progesterone are both bioidentical — they have the same molecular structure as the body’s own hormones. The phrase as used in compounding pharmacies usually refers to:
- Custom-compounded preparations (creams, troches, pellets) not subject to FDA approval
- Variable dosing — pellets in particular can produce supraphysiologic levels
- Often include estriol or testosterone in unstandardized doses
- Lack of standard purity, potency, and quality testing
- Sometimes promoted with claims (cancer protection, anti-aging) not supported by evidence
NAMS and ACOG recommend FDA-approved hormone therapy over compounded preparations except in rare cases of true allergy or specific dose needs not commercially available.
Non-Hormonal Alternatives for Vasomotor Symptoms
For women who cannot or choose not to use HRT:
- Paroxetine (low-dose, FDA-approved for hot flashes)
- Venlafaxine, desvenlafaxine
- Escitalopram, citalopram
- Gabapentin (often dosed at bedtime for night sweats)
- Pregabalin
- Clonidine (less commonly used due to side effects)
- Fezolinetant (Veozah) — newer NK3 receptor antagonist, no hormonal effects
- Cognitive behavioral therapy
- Mindfulness and clinical hypnosis
- Lifestyle — cool environment, breathable clothing, trigger avoidance
Vaginal Estrogen for Local Symptoms
Vaginal dryness, painful intercourse, recurrent UTIs, and urinary urgency — collectively the genitourinary syndrome of menopause — affect a majority of postmenopausal women, often for decades. Local vaginal estrogen is highly effective and has very low systemic absorption:
- Vaginal cream (Estrace, Premarin) — typically nightly, then 2 to 3 times per week
- Vaginal tablet (Vagifem) — twice weekly
- Vaginal insert (Imvexxy) — twice weekly
- Vaginal ring (Estring) — every 3 months
- Systemic absorption is minimal — generally safe even in women who cannot use systemic HRT
- Non-hormonal alternatives: moisturizers (Replens), lubricants for intercourse, ospemifene (SERM)
How Long to Stay on HRT
No fixed duration — the NAMS position is “individualize the duration based on goals of treatment, symptoms, and individual risk factors.” Many women take HRT for 5 to 10 years; some longer when symptoms persist and the risk-benefit balance remains favorable. Periodic reassessment (yearly is reasonable) keeps the decision active rather than default. When stopping, gradual tapering reduces rebound symptoms for many women.
When to See a Specialist
- Considering HRT for the first time and want a coordinated diabetes + menopause plan
- Hot flashes interfering with sleep or work
- Vaginal symptoms affecting quality of life
- Personal or family history of breast cancer or clots
- Cardiovascular disease established
- Persistent bleeding on HRT
- Wanting to discontinue or change HRT
For more on this stage of life, see our companion guides on menopause and diabetes, perimenopause and blood sugar, weight gain in menopause with diabetes, and how to stop insulin resistance in menopause.
The Bottom Line
Hormone replacement therapy and diabetes can coexist — diabetes is not a contraindication, and many women with diabetes are good candidates for HRT when symptoms warrant. Transdermal estrogen is generally preferred over oral because it bypasses hepatic first-pass effects, lowering risks of clots, triglyceride changes, and gallbladder issues. The timing hypothesis supports starting HRT within 10 years of menopause or before age 60 for the most favorable risk-benefit balance. Most studies show modest improvement in insulin sensitivity and A1C on HRT. Compounded “bioidentical” preparations are not FDA-approved and have purity and dosing concerns — FDA-approved estradiol and micronized progesterone are also bioidentical and have predictable dosing. Vaginal estrogen for local symptoms is highly effective and very low absorption, suitable for almost all women. Talk to your endocrinologist and a menopause-trained clinician about whether HRT fits your symptoms, risk factors, and goals.
